COX-2 as a target for cancer chemotherapy.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 2
Abstract
Cyclooxygenase-1 and -2 (COX-1/2) catalyze the initial step in the formation of prostaglandins. Very recently their role in carcinogenesis has become more evident. They influence apoptosis, angiogenesis, and invasion, and play a key role in the production of carcinogens. Usually, a high level of COX-2 expression is found in cancer cells. Large epidemiological trials studying users and non-users of aspirin have shown that cyclooxygenase inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) could be of benefit against the development and growth of malignancies. Moreover, clinical trials in patients with familial adenomatosis polyposis syndrome have shown the efficacy of selective COX-2 inhibitors in the reduction of the number and size of colorectal polyps. Several preclinical studies show promising results with combinatorial treatments of either chemotherapy or radiotherapy with COX inhibitors. Preclinical studies with the simultaneous use of inhibitors of the epidermal growth factor receptor and COX-2 inhibitors have shown also promising results. Encouraging results from the first clinical trials combining chemotherapy with COX-2 inhibitors in patients with cancer in the advanced and neoadjuvant setting have recently been reported. Thus, it appears that targeting the COX-2 pathway is a promising strategy in the prevention and treatment of solid tumors.
Authors and Affiliations
Nilanjan Ghosh, Rituparna Chaki, Vivekananda Mandal, Subhash Mandal
Keywords
Related Articles
- EP ID EP139497
- DOI -
- Views 79
- Downloads 0
1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity.
The aim of this study was to establish the antagonistic effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) on NMDA receptors and its neuroprotective abilities on primary cultures of rat cerebellar granule cells...
Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures.
The majority of studies on neuroprotection tested potentially protective compounds given before, simultaneously or shortly after damage. Such procedures are greatly different from the situation faced in clinical practice...
Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke.
Our goal was to analyze the effects of treatment with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (simvastatin, 40 mg/day) on serum S100BB and tau protein levels during the acute ischemic stroke...
Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum.
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with selective loss of dopaminergic neurons in substantia nigra pars compacta. Among the proposed mechanisms of dopaminergic degeneration, o...
Proton pump (H(+)/K(+)-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats.
Background: Alendronate can induce esophagitis and stomach ulceration requiring the concurrent use of drugs which decrease HCl production. The aim of the present study was to investigate the effect of concurrent administ...